Patient description: 19 yo Hispanic female G1P1 at 32+ 6 weeks of gestational age presented to the OB clinic for routine follow up complaining of mild headache and leg swelling. Primary evaluation revealed BP of 146/99 and urine dipstick with 3+ proteins. Her BP and U/A were normal in previous visit. Repeat BP a few hours later is 150/100 mmHg. Laboratory studies showed a normal hematocrit, platelet count, and liver transaminase levels. She is complaining of fatigue but no fever or chills. She is also suffering of headaches with no vision changes. No shortness of breath, cough, chest pain, orthopnea and palpitations or skin rash were observed. Her physical exam was negative for abdominal pain, change in bowel habits, nausea, vomiting, dysuria, frequency, hematuria or frothy urine. Leg swelling was observed with no arthralgia or back pain. She has no specific past medical issues and only uses prenatal vitamins. Her family history is positive for DM type 2 and HTN. She is a social alcohol consumer with the negative history of smoking or drug use. She is only have one partner in past 2 years and didn't have any contraceptive methods since 2 years ago. Her BMI was 24 at the first

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Migraine male or female, in otherwise good health, 18 to 65 years of age. 2. history of frequent episodic migraine (3-14 migraine days per month) (with or without aura) according to the International Classification of Headache Disorders-3beta for at least 3 months. 3. onset of migraine before age 50. 4. stable history of migraine at least 3 months prior to screening. 5. not currently taking a migraine preventive or has been taking preventive for at least 30 days prior to screening and agrees to not start, stop, or change medication and/or dosage during the study period. 6. if female of childbearing potential, has a negative urine pregnancy test at Visits 1-5 and uses, or agrees to use, for the duration of the study, a medically acceptable form of contraception as listed complete abstinence from intercourse from 2 weeks prior to administration of study drug, throughout the study, and for 7 days after completion or premature discontinuation from the study; surgically sterile (hysterectomy or tubal ligation or otherwise incapable of pregnancy); sterilization of male partner when in a monogamous relationship; intrauterine device with published data showing lowest expected failure rate is less than 1% per year; double barrier method (i.e., 2 physical barriers OR 1 physical barrier plus spermicide) for a least 1 month prior to Visit 1 and throughout study; or hormonal contraceptives for at least 3 months prior to Visit 1 and throughout study. 7. completion of online diary must be ≥ 80% compliance, unless otherwise approved by the Sponsor and/or Clinvest  unable to understand the study requirements, the informed consent, or complete headache records as required per protocol. 2. pregnant, actively trying to become pregnant, or breast-feeding. 3. diagnosed with International Classification of Headache Disorders-3beta for Chronic Migraine within 3 months prior to screening, at the time of screening, and/or during the baseline period. 4. experienced the following migraine variants: basilar migraine, aura without headache, familial hemiplegic migraine, complicated migraine, ophthalmoplegic migraine and retinal migraine within the last year. 5. history of medication overuse headache (MOH) (Appendix II) in the 3 months prior to study enrollment or during the baseline phase. 6. history of medication overuse (MO) of ergotamines, triptans, opioids, analgesics, and combination therapies, as defined by ICHD-3beta and/or MO during baseline period. 7. history of substance abuse and/or dependence, in the opinion of the Investigator. 8. history of impaired renal function that, in the investigator's opinion, contraindicates participation in this study. 9. unstable neurological condition or a significantly abnormal neurological examination with focal signs or signs of increased intracranial pressure. 10. suffers from a serious illness, or an unstable medical condition, one that could require hospitalization, or could increase the risk of adverse events. 11. has significant risk of suicide, defined as a "yes" answer to any of the following questions on the Columbia-Suicide Severity Rating Scale (C-SSRS), either at the screening visit (when assessing the prior 12 months) or at visit 2 (when assessing time since the screening visit): 1. Questions 4 or 5 on the suicidal ideation section 2. Any question on any item in the suicidal behavior section 12. any psychiatric disorder with psychotic features, and/or any other psychiatric disorder not stable or well controlled, that would interfere in their ability to complete study activities. 13. hypersensitivity, intolerance, or contraindication to the use of magnesium L-lactate dehydrate or any of its components. 14. received any investigational agents within 30 days prior to Visit 1. 15. plans to participate in another clinical study at any time during this study